In 2018, drugs for rare conditions such as beta-thalassemia and forms of amyloidosis made it onto the approval mainstage in addition to drugs for more common diseases such as cancer. The gene-editing technology CRISPR slowly made strides into the therapeutic realm, while drugs for Alzheimer’s disease continued to falter, leaving a wide gap that is still in need of filling.
This is a preview of subscription content, log in via an institution to check access.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chakradhar, S. Treatments that made headlines in 2018. Nat Med 24, 1785–1787 (2018). https://doi.org/10.1038/s41591-018-0292-3
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-018-0292-3
- Springer Nature America, Inc.